News and Trends 1 Nov 2018 Llama Antibodies Could Be the Key to Universal Flu Prevention …or different targets.” Indeed, the antibody developed by the group was built using four different llama antibodies, two targeting influenza A viruses and two targeting influenza B viruses to cover… November 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Sponsored by Allucent 23 Sep 2025 The Netherlands: A strategic gateway for biotech clinical trials …she says. To ensure high-quality clinical trial performance, the CRO has built the “Allucent Centers of Expertise” or ACEs for specific complex therapeutic areas like oncology (including Antibody-Drug Conjugates, or… September 23, 2025 - 7 minutesmins - By Francina Agosti Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2017 Novartis Negotiates its Way into the US Migraine Market …drug candidates directed at Alzheimer’s and migraine, under which Amgen received the rights for the U.S., Canada, and Japan, while Novartis was left in charge of the residual markets. Now,… April 25, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2022 Astellas gastric cancer drug meets phase 3 primary endpoint …that includes capecitabine and oxaliplatin). Zolbetuximab is an investigational first-in-class claudin-18.2 (CLDN18.2) targeted monoclonal antibody, for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric… December 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2019 German Alzheimer’s Drug Backed with €43M After Biogen’s Surprise Turnaround …an upcoming European phase IIb trial of Vivoryon’s lead candidate small molecule drug in around 250 patients with Alzheimer’s disease, the most common form of dementia. Results are expected in… October 24, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2018 Yet Another Checkpoint Inhibitor Goes to Trial with Bavarian Nordic’s Cancer Vaccine …BMS’s Opdivo, an antibody binds to the PD-1 receptor, in late 2016. They also partnered with Roche to test CV301 with Roche’s Tecentriq, an antibody which binds to the ligand… February 28, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Galapagos to acquire CellPoint and AboundBio to advance cell therapies …an innovative, scalable, decentralized and automated point-of-care cell therapy supply model as well as a next-generation fully human antibody-based therapeutics platform. Galapagos said the goal is to expand the current… June 22, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2022 Financing round of $21M completed for drug to treat autoimmune diseases …entered into the worldwide agreement for the investigational anti-CD38 monoclonal antibody, CID-103, for the treatment, prevention, and diagnosis of autoimmune diseases, conditions, and disorders in humans. Strong activity CID-103 is… July 11, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 21 May 2020 What 2019 Can Teach About European Biotech Investments Going Forward …the Nasdaq Stock Exchange. The Danish company Genmab also pulled off a €450M Nasdaq IPO to fund the development of its antibody drug pipeline. In addition to these huge fundraises,… May 21, 2020 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 5 Dec 2022 The biggest private biotech investments in November 2022 …cheaply. Second place went to CatalYm in Germany. The firm specializes in the development of anti-cancer antibodies and is testing its lead candidate in clinical trials. Topping the healthcare biotech… December 5, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 26 Jun 2024 Biotech megadeals: Exploring the surge in $100M+ deals …molecule therapies driving megadeals in the biotech industry. “The Inflation Reduction Act granted large molecule therapies (gene and protein-based therapies, immunotherapies, hormonal regulators, and antibody-drug conjugates), a much longer patent… June 26, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jan 2018 Novartis Takes Genmab’s Leukemia Drug Off the Market …a monoclonal antibody that targets CD20 proteins on the surface of leukemia cells. The antibody binds to the proteins, alerting the immune system, which can then hunt down and kill… January 22, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email